Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
Of the big oncology deals since 2016, there are still plenty that could go either way.
The 2024 AACR abstract title drop features several noteworthy clinical studies.
Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.